

Ontogeny of Scaling Factors for Pediatric Physiology-Based Pharmacokinetic Modeling and Simulation: Microsomal Protein Per Gram of Liver^S

J. Steven Leeder, Jean C. Dinh,¹ Andrea Gaedigk, Vincent S. Staggs, Bhagwat Prasad, and Robin E. Pearce

Certara, Princeton, NJ (J.C.D.); Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics and Children's Mercy Research Institute, Children's Mercy Kansas City, Kansas City, Missouri (J.S.L., J.C.D., A.G., V.S.S., R.E.P.); Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington (B.P.)

Received July 22, 2021; accepted October 20, 2021

ABSTRACT

Microsomal protein per gram of liver (MPPGL) is an important scaling factor for bottom-up physiology-based pharmacokinetic modeling and simulation, but data in pediatrics are limited. Therefore, MPPGL was determined in 160 liver samples from pediatric ($n = 129$) and adult ($n = 31$) donors obtained from four sources: the University of Maryland Brain and Tissue Bank (UMBTB), tissue retrieval services at the University of Minnesota and University of Pittsburgh, and Sekisui-Xenotech. Tissues were homogenized and subjected to differential centrifugation to prepare microsomes, and cytochrome c reductase activities in tissue homogenates and microsomes were used to estimate cytochrome P450 reductase (POR) activity as a marker of microsomal recovery; microsomal POR content was also assessed by quantitative proteomics. MPPGL values varied 5- to 10-fold within various age groups/developmental stages, and tissue source was identified as a contributing factor. Using a “trimmed” dataset comprised of samples ranging from 3 to 18 years of age common to the four sources, POR protein abundance and activity in microsomes and POR activity in homogenates was lower in UMBTB samples (autopsy) compared

with other sources (perfused/flash-frozen). Regression analyses revealed that the UMBTB samples were driving an apparent age effect as no effect of age on log-transformed MPPGL values was observed when the UMBTB samples were excluded. We conclude that a mean \pm SD MPPGL value of 30.4 ± 1.7 mg/g is representative between one month postnatal age and early adulthood. Potential source effects should be considered for studies involving tissue samples from multiple sources with different procurement and processing procedures.

SIGNIFICANCE STATEMENT

Microsomal protein per gram of liver (MPPGL) is an important scaling factor for bottom up PBPK modeling and simulation, but data in pediatrics are limited. Although MPPGL varies 5- to 10-fold at a given developmental stage, a value of 30.4 ± 1.7 mg/g (mean \pm SD) is representative between one month postnatal age and early adulthood. However, when tissue samples are obtained from multiple sources, different procurement and processing procedures may influence the results and should be taken into consideration.

Introduction

The value of pharmacokinetic (PK) modeling and simulation in the design and conduct of pediatric clinical trials is now well recognized by

Tissues used in this study were acquired from publicly supported tissue repositories, including the National Institutes of Health (NIH)-funded University of Maryland Brain and Tissue Bank for Developmental Disorders (funded by NIH contract HHSN275200900011C, Ref. No. #N01-HD-9-0011) and The Liver Tissue Cell Distribution System (funded by NIH contract #N01-DK-7-0004/HHSN267200700004C). The work was supported by grants P50 HD090258 (J.S.L.) and R01-HD081299 (B.P.) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development.

No author has an actual or perceived conflict of interest with the contents of this article.

¹Current affiliation: Certara, Princeton, New Jersey.

<https://dx.doi.org/10.1124/dmd.121.000623>.

^S This article has supplemental material available at dmd.aspetjournals.org.

the pharmaceutical industry and is also routinely employed by regulatory agencies tasked with evaluating data presented in support of pediatric labeling (Germovsek et al., 2019). Clinically, PK modeling and simulation plays an important role in describing drug disposition and response on a population basis, and the identification of factors that account for observed inter-individual variability in pediatric or other patient populations can be leveraged to develop models to individualize treatment (Krekels et al., 2017; Neely et al., 2018). “Top down” models, consisting of a limited number of empirical equations, describe the distribution of data observed for a given drug in a defined population, but the ability to extrapolate from one drug to another in the population of interest, or from one patient population to another, is limited. On the other hand, “bottom up” physiology-based pharmacokinetic (PBPK) models combine drug-specific and system-specific information, allowing a variety of physiochemical, in vitro preclinical and in vivo clinical data to be integrated, allowing reproduction of the underlying anatomy and physiology of the biologic system (Maharaj and Edginton, 2014).

ABBREVIATIONS: LTCDS, Liver Tissue Cell Distribution System; MPPGL, microsomal protein per gram liver; PBPK, physiology-based pharmacokinetic; PK, pharmacokinetic; POR, cytochrome P450 oxidoreductase; UMBTB, University of Maryland Brain and Tissue Bank for Developmental Disorders; AHTU, Association of Human Tissue Users; AKR1C4, aldo-keto reductase family 1, member C4; CPPGL, cytosolic protein per gram liver; HLM, human liver microsomes; LC/MS/MS, liquid chromatography with tandem mass spectroscopy.

Given the relative abundance of data generated in adults or adult-derived systems, multiple strategies have been applied to scale values for parameters, such as plasma clearance in vivo or intrinsic clearance of unbound drug in vitro, from adults to pediatric patients of various ages and developmental stages. Allometric scaling solely on the basis of weight has limitations, especially in newborns, infants, and young children (Edginton and Willmann, 2006; Mahmood et al., 2014; Calvier et al., 2017); these limitations have been addressed by adding maturation functions that characterize the developmental trajectories of drug-metabolizing enzymes contributing to drug clearance (Calvier et al., 2019).

“Bottom up” PBPK models require additional scaling factors—one that addresses the changes in liver volume that accompany growth and development, and one that scales in vitro intrinsic clearance of unbound drug to hepatic clearance (CL_H). Johnson et al. (Johnson et al., 2005) compiled a dataset of 5,036 liver volume measurements from nine different published studies, and after assessment of several potential covariates, determined that a model expressing liver volume as a function of body surface area (liver volume = $0.722 \times BSA^{1.176}$) best described the change in liver volume between birth and 18 years of age. The group also found that the model predicted liver volume in adults with precision and accuracy that exceed almost all (10/11) published adult models (Johnson et al., 2005).

Data characterizing the second scaling factor, microsomal protein per gram of liver (MPPGL), are much more limited, especially across the pediatric age range. In the largest study to date ($n = 128$), MPPGL values from adult samples aged 20 to 75 years of age were not normally distributed and varied 19-fold from 6.7 to 128.0 mg/g liver, with a mean \pm SD of 39.5 ± 21.6 mg/g liver (Zhang et al., 2015). This mean MPPGL value of 40 mg/g is in agreement with the value presented by Hakooz et al. (Hakooz et al., 2006) as well as the conclusion of a meta-analysis of several previously published studies that includes the Hakooz study (Barter et al., 2007; Barter et al., 2008). However, in this analysis, samples covering the period between birth and adulthood (18 years of age) were limited as only one pediatric sample (11 years of age) was reportedly included in the original meta-analysis (Barter et al., 2007); in a follow-up study, the meta-analysis dataset was supplemented with four additional pediatric donors aged 2, 4, 9, and 13 years of age (Barter et al., 2008). Thus, available data regarding the developmental trajectory of MPPGL include only five time points between 2 and 13 years of age and are the basis of age-dependent MPPGL estimates used in pediatric PBPK models, such as the value of 26 mg/g used in a recent PBPK modeling and simulation study in infants (Salerno et al., 2021). Therefore, the purpose of this investigation was to address the paucity of data describing the ontogeny of MPPGL between birth and adulthood given their importance as scaling factors for PBPK modeling and simulation.

Materials and Methods

Materials and Reagents. β -NADPH and cytochrome *c* derived from horse heart were purchased from Sigma Aldrich Chemical Co. (St. Louis, MO, USA). Sodium dithionite was obtained from Merck (Damstadt, Germany). Pooled human liver microsomes ($n = 200$ donors, mixed gender, 100 male and 100 female, Lot No. 1410230) and pooled human liver homogenate ($n = 20$ donors, mixed gender, Lot No. 1510072) were purchased from Xenotech, LLC, (Lenexa, KS, USA) and used as controls in the cytochrome *c* reductase assay. All other chemicals were of reagent grade and were purchased from either Sigma Aldrich Chemical Co. or Thermo-Fisher Scientific (Fairlawn, NJ).

Liver Samples. A total of 160 liver samples ($n = 129$ pediatric and $n = 31$ adult) were included in this study. The primary sources of tissue were the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)-supported tissue retrieval program at the Brain and Tissue Bank for Developmental Disorders at the University of Maryland (UMBTB, Baltimore,

MD (now the University of Maryland Brain and Tissue Bank, and a member of the NIH NeuroBioBank network); $n = 60$, including $n = 52$ pediatric, and $n = 8$ adult samples) and the NIH-supported Liver Tissue Cell Distribution System (LTCDS), with sites at the University of Minnesota ($n = 34$ pediatric) and the University of Pittsburgh ($n = 37$, comprised of $n = 14$ pediatric and $n = 23$ adult samples). Additional pediatric liver samples were obtained from In Vitron (Tucson, AZ; $n = 4$), the University of Miami ($n = 1$), and the Association of Human Tissue Users ($n = 1$). In addition, homogenates and microsomes isolated from pediatric livers for this study ($n = 23$) were donated by Xenotech, LLC. (Lenexa, KS; now Sekisui Xenotech, Kansas City, KS). The distribution of samples by tissue source and age group is provided in Supplemental Table 1, and available demographic data, including reported cause of death (when available), for all samples is listed in Supplemental Table 2. Overall, postnatal samples ranged in age from birth to 79 years of age; 57/160 (35.6%) were female, 102 (63.8%) were male, and sex was unknown for one sample. Race was reported as African American for 40 samples (25.0%), Caucasian for 76 samples (47.5%), Hispanic for 7 samples (4.4%), and Native American and Pacific Islander for one sample each; race information was not available for 35 samples (21.9%), including all samples from the University of Minnesota ($n = 34$). Use of the tissue samples was classified as non-human subjects research by the Children's Mercy Pediatric Institutional Review Board. Tissues were stored at -70°C or below prior to preparation of subcellular fractions.

Assessment of RNA Integrity. As a surrogate measure of liver tissue quality for MPPGL determination, RNA integrity was assessed at the time of tissue processing. Briefly, total RNA was extracted from an average of 35 mg of human liver tissue using a Qiagen RNeasy kit (Qiagen, Valencia, CA) following the manufacturer's protocol, including the on-column DNase I digestion step. The quantity of isolated RNA was assessed using a NanoDrop 1000 instrument which informed the amount of sample for subsequent analysis on an Experion StdSens RNA microfluidic chip (Bio-Rad, Hercules, CA; cat #700-7103). This Experion RNA analysis allowed us to determine total RNA and mRNA integrity, purity, and concentration. Specifically, the generated electropherogram enabled evaluation of the RNA sample for degradation. The RNA quality index (RQI) is calculated by the Experion software, with an RQI of 1 representing highly degraded and an RQI of 10 representing high-quality total RNA. Further details on the method, representative examples and the development and validation of RQI as an RNA quality indicator can be obtained from Bio-Rad technical note 5761 available at <https://www.gene-quantification.de/Bio-Rad-bulletin-5761.pdf>.

Preparation of Pediatric Liver Homogenates and Microsomes. Human liver microsomes were prepared by differential centrifugation, essentially as described by Lu and Levin (Lu and Levin, 1972). Briefly, pre-weighed, frozen liver samples were placed in homogenizing buffer (~ 3 mL/g liver; 50 mM Tris.HCl, pH 7.4 at 4°C , containing 150 mM KCl and 2 mM EDTA) and allowed to thaw at 4°C . Liver samples were quickly minced with dissecting scissors on ice, placed in Potter-Elvehjem-type glass mortars (round-bottom) and homogenized on ice with a Polytron tissue homogenizer (Kinematica USA, Bohemia, NY, USA) using 3–4 second bursts of grinding for 1–2 passes. Liver samples were subjected to further homogenization (3–4 strokes on ice, 2–3 passes) in the glass mortars with Teflon pestles utilizing a motor-driven tissue homogenizer (Caframo Model BDC-3030, Warton, ON, Canada). Homogenates were placed into low-speed centrifuge tubes, filled with homogenization buffer, briefly mixed, an aliquot of homogenate removed, and the volume recorded. Subsequently, nuclei and lysosomes were removed from the homogenate by centrifugation ($800 g_{\text{max}}$ for 15 minutes at 4°C). The resulting supernatant was further centrifuged ($12,000 g_{\text{max}}$ for 20 minutes at 4°C), and the supernatant fraction was subjected to ultra-centrifugation ($105,000 g_{\text{max}}$ for 70 minutes at 4°C). The resulting supernatant (cytosol) was stored at -80°C for future determination of cytosolic protein per gram liver ontogeny. The pellet (microsomal fraction) was removed from the centrifuge tube, transferred to a low-volume glass mortar, manually re-suspended in 0.25 M of sucrose with a Teflon pestle, and stored at -80°C until use. Protein concentrations were determined with a Micro BCA Protein Assay kit (Pierce Chemical Co., Rockford, IL, USA) using bovine serum albumin (Sigma, St. Louis, MO, USA) as the standard.

Cytochrome C Reductase (POR) Activity. In vitro cytochrome P450 reductase (POR) activity was used as the marker for microsomal content and enzyme activity assays were performed in 96-well microtiter plates. Incubations (200 μL) contained human liver homogenate (typically 30 μg of homogenate protein, range 9.5–65 μg), or microsomes (typically 3 μg of microsomal protein,

range 3–21 μg), potassium phosphate buffer (350 mM, pH 7.4), MgCl_2 (3 mM), EDTA (1 mM), and cytochrome *c* (50 μM) at the final concentrations listed. Although homogenate studies were conducted in a matrix with higher protein concentrations relative to the microsomal studies, the concentration of cytochrome *c* present in the performed incubations is expected to be above enzyme saturating concentrations such that free, unbound concentrations of substrate are comparable in homogenates and microsomes, should higher non-specific binding be present in the latter. Each microtiter plate contained oxidized and reduced cytochrome *c* standards created by adding 50 μL of water or sodium dithionite (250 mg/mL), respectively, to each standard-containing well for a total volume of 250 μL . Plates were pre-incubated at $30 \pm 1^\circ\text{C}$ for 5 minutes directly in a Bio-Tek Synergy HT multi-mode micro-titer plate reader, and reactions were initiated in sample wells by the addition of 50 μL of β -NADPH (500 μM). Absorbance (550 nm) was recorded with the plate reader operating in kinetic mode at 25 second scan intervals for 5 minutes. POR activity was defined as the rate of reduction of cytochrome *c*, determined by measuring the rate of change in optical density (OD) in the linear portion of the kinetic curves and calculated using Eq. 1:

$$\text{POR Activity}_{(\text{nmol/min/mg})} = \frac{\text{Amount of cytochrome } c(\text{nmol/well})}{\text{OD}_{\text{cyt } c_{\text{reduced}}} - \text{OD}_{\text{cyt } c_{\text{oxidized}}}} \times \frac{\Delta\text{OD}}{\Delta T} \times \frac{1}{\text{mg protein/well}} \quad (1)$$

where $\text{OD}_{\text{cyt } c_{\text{oxidized}}}$ is the mean of optical densities from wells containing oxidized cytochrome *c*, $\text{OD}_{\text{cyt } c_{\text{reduced}}}$ is the mean of optical densities from wells containing reduced cytochrome *c* and $\Delta\text{OD}/\Delta T$ is the mean change in OD during the linear portion of the curve.

Estimation of Liver Microsomal Protein Content. The total amount of homogenate protein obtained per gram of starting liver tissue was calculated as:

$$\frac{\text{Protein}_{\text{Hom}}(\text{mg})}{\text{Liver Weight}(\text{g})} = \frac{\text{Protein Concentration}_{\text{Hom}}(\text{mg/mL}) \times \text{Volume}_{\text{Hom}}(\text{mL})}{\text{Liver Weight}(\text{g})} \quad (2)$$

where $\text{Protein}_{\text{Hom}}$ and $\text{Volume}_{\text{Hom}}$ represent the total amount and volume of homogenate prepared from the starting amount of liver tissue, respectively.

MPPGL was corrected for recovery of microsomal protein during the preparation procedure using the following equation (Wilson et al., 2003; Barter et al., 2008):

$$\text{MPPGL}(\text{mg/g}) = \frac{\text{POR Activity}_{\text{Hom}}(\text{nmol/min/mg})}{\text{POR Activity}_{\text{Mic}}(\text{nmol/min/mg})} \times \frac{\text{Protein}_{\text{Hom}}(\text{mg})}{\text{Liver Weight}(\text{g})} \quad (3)$$

where $\text{POR Activity}_{\text{Hom}}$ and $\text{POR Activity}_{\text{Mic}}$ represent the rate of reduction of cytochrome *c* in the cellular homogenate and microsomal fractions, respectively.

Recovery of microsomal protein from liver homogenate was determined as:

$$\text{Microsome Recovery} = \frac{\text{PORAct}_{\text{Mic}}(\text{nmol/min/mg}) \times \text{Protein Conc}_{\text{Mic}}(\text{mg/mL}) \times \text{Volume}_{\text{mic}}(\text{mL})}{\text{PORAct}_{\text{Hom}}(\text{nmol/min/mg}) \times \text{Protein Conc}_{\text{Hom}}(\text{mg/mL}) \times \text{Volume}_{\text{Hom}}(\text{mL})} \quad (4)$$

Assessment of POR Content by Quantitative Proteomics. POR content was determined in a subset of samples ($n = 123$) by a surrogate peptide-based liquid chromatography with tandem mass spectroscopy (LC-MS/MS) method (Bhatt and Prasad, 2018). The surrogate peptide of POR quantification (Supplemental Table 3) was selected based on previously reported criteria (Bhatt and Prasad, 2018) and was obtained from New England Peptides (Boston, MA). A previously optimized protocol for trypsin digestion of microsomal proteins and the sample preparation for liquid chromatography with tandem mass spectroscopy analysis was adopted (Bhatt et al., 2018). Briefly, 60 μL of the human liver microsome (2 mg/mL) sample was denatured and reduced by incubation with 40 μL of ammonium bicarbonate digestion buffer (100 mM, pH 7.8) and 10 μL of 100 mM dithiothreitol at 90°C for 5 minutes. The resultant solution was alkylated by adding 20 μL of 200 mM iodoacetamide at room temperature for 20 minutes. The processed protein was then precipitated using ice-cold methanol (500 μL) and chloroform (200 μL). Water (400 μL) was added to the mixture, and the sample was vortexed and centrifuged at $12,000 \times g$ for 5 minutes. The upper

solvent layer was carefully removed, and the protein pellet was washed with 500 μL of ice-cold methanol followed by centrifugation at $12,000 \times g$ for 5 minutes. The final protein pellet was dissolved in 60 μL of ammonium bicarbonate. The samples were then digested by trypsin (protein:trypsin ratio of $\sim 50:1$) in a final volume of 80 μL at 37°C for 16 hours. The reaction was stopped by adding 20 μL of peptide internal standard (prepared in 70% acetonitrile in water containing 0.1% formic acid) and 10 μL of the neat solvent (70% acetonitrile in water containing 0.1% formic acid). The samples were centrifuged at $4000 \times g$ for 5 minutes. The calibration curve standards were prepared by spiking standard working solutions of peptides (prepared in 70% acetonitrile in water containing 0.1% formic acid) into ammonium bicarbonate buffer. Eight calibration standards were used to produce a range of on column amounts from 0.3 to 150 fmol. For each standard, working stock solutions of the peptide (10 μL) were added in the last step instead of the neat solvent. All of the human liver microsome samples were digested and processed in triplicate.

Protein quantification was performed using a triple-quadrupole MS instrument (Sciex Triple Quad 6500, Concord, ON) in ESI positive ionization mode coupled to an Acquity UPLC, I-class (Waters, Milford, MA). Five μL of each trypsin digested sample was injected onto the column (ACQUITY UPLC HSS T3 1.8 μm , C_{18} 100A; 100×2.1 mm, Waters, Milford, MA). Surrogate light and heavy (internal standards) peptides were monitored using instrument parameters provided in Supplemental Table 3. The LC-MS/MS data were processed using Analyst 1.6.2 version software (Sciex, Concord, Ontario). The lower limit of quantification (LLOQ) of POR peptide was 0.07 pmol/mg protein. The protein expression data are reported as the mean and standard deviation (SD) of values obtained in at least three experiments.

Data and Statistical Analyses. The distribution of raw and log-transformed MPPGL values was assessed for normality by visual inspection of the normal quantile plot and by the Shapiro Wilk W test (Supplemental Fig. 1). To characterize the relationship between log-transformed MPPGL (log MPPGL) and developmental stage, liver samples were stratified and characterized as recommended by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Williams et al., 2012). Specifically, samples were categorized as neonatal (birth to 28 days; $n = 3$), infant (29 days to 12 months; $n = 17$), toddler (13 months to 2 years; $n = 9$), early childhood (2 to 5 years; $n = 21$), middle childhood (6 to 11 years; $n = 32$), early adolescence (12–18 years; $n = 47$), and late adolescence (19–21 years; $n = 0$). Adult samples were arbitrarily divided into two additional categories of younger adult (21 to 50 years; $n = 16$) and older adult (> 50 years; $n = 15$).

A subset of the data were used to assess the potential influence of factors related to tissue source. The data subset for this analysis, hereafter referred to as the “trimmed” dataset, comprised samples from an age range, 3 to 18 years, that was common to the major sources of samples: UMBTB, LTCDS sites at Minnesota and Pittsburgh and Sekisui-Xenotech. Comparisons of the tissue sources were conducted using analysis of variance (ANOVA) followed by post-hoc analysis using Tukey’s Honestly Significant Difference, or Welch’s ANOVA in the presence of unequal variance. In addition, a linear model was fit to the trimmed data set, modeling $\log(\text{MPPGL})$ as a function of sample source, sex, POR_{Hom} value, age, and age (centered)². The resulting source effects were taken as estimates of the effect of source after controlling for any effects of sex, POR_{Hom} value, and age. Finally, each $\log(\text{MPPGL})$ value was adjusted in the full sample by subtracting the appropriate source effect estimate. The effectiveness of the adjustment was checked by refitting the model to the source-adjusted $\log(\text{MPPGL})$ values for the trimmed sample and verifying that all source effects were zero. The remaining analyses were carried out using these source-adjusted $\log(\text{MPPGL})$ values. Because source effects could not be assessed for the single sample sources (Miami and Association of Human Tissue Users samples), their $\log(\text{MPPGL})$ values were not adjusted.

Comparisons across age strata were conducted by ANOVA followed by post-hoc analysis using Tukey’s Honestly Significant Difference test. All statistical analyses were conducted in JMP Pro version 14.2.0, SAS version 9.4 (SAS Institute Inc., Cary, NC), and R (R Core Team, Vienna, Austria). The relationship between source-adjusted $\log(\text{MPPGL})$ and age as a continuous variable was also assessed using GraphPad Prism v8 (GraphPad Software, San Diego, CA) and an asymptotic exponential or sigmoid E_{max} with Hill coefficient models (Anderson and Holford, 2008) to characterize the developmental trajectory up to age 18 for use in PBPK applications. Output for the source-adjusted MPPGL model was compared with values up to age 18 years generated using the polynomial function reported by Barter et al. (2008):

$$\text{MPPGL}(\text{mg/g}) = 10^{(1.047 + 0.01579\text{age} - 0.000382\text{age}^2 + 0.00000237\text{age}^3)}$$

Results

General Distribution of MPPGL Values. Overall, postnatal MPPGL values varied 10-fold (7.9 mg/g to 80.8 mg/g) across the entire age range of birth to 79 years and were not normally distributed based on visual inspection of normal quantile plots and the Shapiro Wilk W test ($P < 0.0001$). Log-transformation of the MPPGL data resulted in normal distributions according to the same criteria (output of the JMP Pro analysis can be found in Supplemental Fig. 1).

The geometric mean for MPPGL in all samples ($n = 160$) was 24.0 mg/g, with a median value of 24.1 mg/g and an interquartile range of 16.6 mg/g to 34.3 mg/g. The distribution of logMPPGL values as a function of age group/developmental stage is presented in Fig. 1A and with age as a continuous variable in Fig. 1B, individual samples and color-coded by tissue source. There were only three samples within the neonatal age range, so they have been combined with the “infant” group and are designated with a white “x” within the corresponding symbol. A summary of the distribution of MPPGL values in each age group/developmental stage is also provided in Table 1.

Variability in MPPGL Values: Contribution of Tissue Source. Inspection of the data presented in Fig. 1A and Table 1 reveals that MPPGL values varied 5- to 10-fold within various age groups/developmental stages. Visual inspection of the data color-coded by source of liver tissue further reveals that several age groups include samples from multiple sources, whereas others (e.g., Group 7, older adults) include samples from a single source. This observation suggests the possibility that source of tissue may confound interpretation of any effect of age on MPPGL values. To assess the relationship between observed MPPGL values and source of liver tissue for preparation of microsomal fractions, the dataset was reduced to a set of samples encompassing an age range (3 years and 18 years of age (early childhood, middle childhood, and early adolescent age groups) that was common to each major source of tissues. This “trimmed” dataset included 92 samples from four tissue sources: UMBTB ($n = 33$), Minnesota ($n = 31$), Pittsburgh ($n = 15$), and Sekisui-Xenotech ($n = 14$); three samples within this age range obtained from Vitron were excluded from the analysis because of the small number of samples that fell within the specified age range. By univariate analysis, all four tissue sources were similar with respect to age and sex (~40% female) but differed with respect to RNA quality; UMBTB samples had lower median (interquartile range) RQI values of 4.7 (3.3, 6.2) compared with 7.4 (6.0, 8.3) for Xenotech samples, 8.8 (8.2, 9.3) for Pittsburgh samples, and 8.9 (8.4, 9.3) for samples from the University of Minnesota source.

The potential tissue source effect on MPPGL was also assessed using POR activity and protein content as measures of microsomal quality. POR activity in liver homogenates and microsomes differed across the tissue sources as assessed by Welch’s ANOVA for unequal variances ($P < 0.0001$; POR activity in the UMBTB samples was lower than the other three sources; Figs. 2A and 2B). Proteomic analysis confirmed that POR protein was significantly lower in the UMBTB samples compared with the other three sources ($P < 0.0001$; Fig. 2C), and POR activity in microsomes expressed relative to absolute POR protein content was likewise significantly lower in the UMBTB samples ($P < 0.0001$; Fig. 2D). The relationship between microsomal POR activity and protein was similar for the UMBTB and non-UMBTB sources in terms of slope and coefficient of determination, but for a given amount of POR protein, activity was approximately 50% lower in the UMBTB samples (Fig. 2E). Finally, microsomal recovery also differed according to tissue source (Fig. 2F), with higher recovery from Sekisui-Xenotech samples ($49.0 \pm 15.8\%$; $P < 0.001$) compared with the other three

sources, LTCDS-Minnesota ($33.7 \pm 10.6\%$), LTCDS-Pittsburgh ($27.3 \pm 9.4\%$) and UMBTB ($27.0 \pm 13.5\%$). Similar results were observed when all postnatal samples for the four sources were considered.

As observed in the parent dataset, MPPGL values of the trimmed dataset were not normally distributed by visual inspection of the frequency histogram and Q-Q plots and the Shapiro-Wilk W test ($P = 0.003$). Therefore, the data were log-transformed and more closely approximated a normal distribution by visual inspection of the frequency histogram and Q-Q plots. Despite the lower POR activities in the UMBTB samples, comparison of logMPPGL values across the four sites revealed that values for the University of Minnesota samples were approximately 50% higher than the other groups by Tukey’s Honestly Significant Difference ($P < 0.0001$; Fig. 3).


Relationship between MPPGL and Postnatal Age: Linear Regression Modeling. After adjusting for source effects as described in Methods, linear models were fitted to the full data set (all sources), the data from all sources except UMBTB, and the UMBTB data alone (Table 2). The first two analyses were limited to ages ranging from 0 to 44 years to allow for full maturation to be achieved. There were only 16 samples in the 45-79 age range, all but one from a single source (Pittsburgh); these were excluded to avoid inordinate influence of data in the tail of the age distribution and over-reliance on data from a single source for this age range. The UMBTB analysis was limited to ages 0 to 25 by excluding two samples with outlying ages (35 and 47). In all models, age was centered at 9 years and expressed in decades. Source-adjusted log(MPPGL) was modeled as a function of sex, POR value (expressed as a z-score), age, and age squared. Respective medians for males and females were 1.34 and 1.36 for logMPPGL (0.1-SD difference, Wilcoxon 2-sample test $P = 0.921$), 14.6 and 19.6 nmol/min/mg protein for POR activity in homogenates, respectively, for males and females (0.36-SD difference, Wilcoxon $P = 0.256$), and 78.9 and 94.4 nmol/min/mg protein, respectively, for males and females for POR activity in microsomes (0.26-SD difference, Wilcoxon $P = 0.177$). Similarly, sex was not a significant factor in the initial model, and the linear model re-fit without sex, resulting in the results presented in Table 2. We explored cubic models, including natural spline models, for the full data set, but these models provided little or no additional explanatory value. Review of the results presented in Table 2 reveals that the 95% confidence intervals for some of the age variables (age and age²) include zero. The confidence intervals including zero are interpreted as zero (i.e., no change in logMPPGL with age) being a plausible value, given the data, for the true regression coefficient, along with every other value covered by the confidence interval.

The prediction equations for each analysis (POR z-score assumed to be zero [i.e., average]) are as follows:

1. All sources $\text{Log}(\text{MPPGL}) = 1.444 + 0.050 * (\text{age in decades} - 0.9) - 0.010 * (\text{age in decades} - 0.9)^2$
2. All sources except UMBTB (“non-UMBTB model”) $\text{logMPPGL} = 1.515 + 0.001 * (\text{age in decades} - 0.9) - 0.094 * (\text{age in decades} - 0.9)^2$
3. UMBTB only (“UMBTB model”) $\text{logMPPGL} = 1.069 + 0.070 * (\text{age.in.decades} - 0.9) - 0.002 * (\text{age.in.decades} - 0.9)^2$

The three models resulting from the regression analysis confirm that the UMBTB samples are driving the apparent age effects when all samples are considered together, as essentially no effect of age on logMPPGL is observed when the UMBTB samples are excluded from the analysis. Thus, the model provides an MPPGL value of $10^{1.515}$ or 32.7 mg/g at the average age of 9 years for the age range of one month

Fig. 1. Relationship between log-transformed MPPGL values and postnatal age. Panel A. Postnatal age is expressed as a categorical variable using NIH-recommended age strata (Williams et al., 2012): Group 1, Infancy (28 days to 12 months of age); Group 2, Toddler (13 months to 2 years of age); Group 3, Early Childhood (2 years to 5 years of age); Group 4, Middle Childhood (6 years to 11 years of age); Group 5, Early Adolescence (12 years to 18 years of age). For reference, Groups 6 and 7 represent Younger Adults (19 years to 50 years of age) and Older Adults (> 50 years of age), using an age of 50 years as an arbitrary cut-off. Box plots were constructed using the “outlier” format in JMP Pro 14.3. Boxes are defined by the first and third quartiles (25th and 75th quantiles, respectively), and the median is indicated by the horizontal line within the boxes; the sample mean is indicated by the dashed horizontal line. The whiskers extend from the ends of the box to the outermost data point that falls within the distance calculated as the third quartile + 1.5*(interquartile range) at the upper bound and the first quartile - 1.5*(interquartile range) at the lower bound; points extending beyond the whiskers are considered outliers. Panel B. Age is presented as a continuous variable, “B” indicates day of “birth”. For both panels, data points are colored according to source of tissues: UMBTB (green), University of Minnesota (red), University of Pittsburgh (blue), Sekisui-Xenotech (gray), Vitron (yellow) and other (University of Miami and Association of Human Tissue Users, one sample each; black). The three points with a black “x” in the center (all from UMBTB; green) represent neonatal samples from the day of birth to 28 days postnatal age.



(the youngest sample in the non-UMBTB sample set) to 25 years, the oldest age included in the analysis; applying the non-UMBTB model to

all samples from birth to 18 years results in a mean \pm SD MPPGL value of 30.4 ± 1.7 mg/g (range 27.4 to 32.7 mg/g), similar to the value of

TABLE 1

Distribution of MPPGL values within each age group or developmental stage according to NICHD-recommended age strata. The dataset included only three neonatal samples (birth to 28 days postnatal age) that were included in the “Infant” group.

Group	Category	N	Median	IQR	Minimum	Maximum	Fold-Range
			(mg/g)	(mg/g)	(mg/g)	(mg/g)	(mg/g)
1	Infant	20	17.3	9.7 – 23.3	8.1	49.1	6.0
2	Toddler	9	24.5	17.9 – 31.6	9.2	44.2	4.8
3	Early Childhood	21	27.7	15.2 – 36.9	11.1	50.2	4.5
4	Middle Childhood	32	24.2	19.3 – 41.8	8.8	57.4	6.5
5	Early Adolescent	47	24.6	18.5 – 32.7	9.9	60.2	6.1
6	Younger Adult	16	25.9	20.4 – 37.2	7.9	81.2	10.3
7	Older Adult	15	32.1	19.8 – 39.5	18.8	66.7	3.5
All Postnatal		160	23.8	18.3 – 34.2	7.9	81.2	10.3

32.1 ± 4.3 mg/g (25.5 to 38.2 mg/g) that is obtained for the same samples using the equation of Barter et al. (Barter et al., 2007).

Relationship between MPPGL and Postnatal Age: Sigmoid Emax Model. Application of a sigmoid Emax model to the same dataset used for the regression analysis failed to reach convergence on parameter estimates, consistent with minimal change in logMPPGL values from 1 month postnatal age to adulthood.

Discussion

Pediatric data describing the developmental trajectory of MPPGL, an important scaling factor for translating drug biotransformation activity in vitro into drug clearance values in vivo for PBPK modeling and simulation, are extremely limited. The goal of this investigation was to address this important knowledge deficit.

Compared with the availability of adult liver tissue, liver tissue from the pediatric age group (defined as birth to 18 years of age for this study and the age range of patients treated in children’s hospitals like our own) is much less common as every attempt will be made to find a suitable pediatric transplant recipient for any pediatric tissue that becomes available. Nevertheless, pediatric tissues for research are available from several academic and not-for-profit groups, such as UMBTB, LTCDS, the National Disease Research Interchange (NDRI; Bethesda, MD) and the Association of Human Tissue Users. Commercial sources of pediatric tissue or subcellular fractions include Xenotech (Kansas City, KS), Corning Gentest (Woburn, MA), Vitron (Tucson, AZ), Cellz Direct (Carlsbad, CA, USA), and PuraCyp (Carlsbad CA, USA), among others. Often, as in our case, tissues are acquired from multiple sources to accumulate sufficiently large numbers to generate robust and useful data, especially in neonates, toddlers and infants for whom extrapolation from adults becomes increasingly more tenuous.

This process, however, is accompanied by concerns related to the impact of variability between tissue sources and interpretation of the resulting data. For example, in the set of samples used for these studies, not all age groups are equally represented among all tissue sources. More specifically, 80% (16/20) of samples in the neonatal+infant age group (birth to 1 year of age) were obtained from a single source, UMBTB. Similarly, the age of the Pittsburgh samples (all adult) is much greater than the age of the Minnesota and UMB samples. Thus, the various tissue sources may differ with respect to the demographic characteristics of the population available through that source.

Further confounding the interpretation of the results is the fact that tissues are procured, maintained, and processed by substantially different procedures and protocols. At one extreme, liver tissue available from the University of Minnesota LTCDS site is snap frozen in liquid nitrogen within 60 minutes of explantation or ischemia start. This requirement is adhered to strictly and specimens outside of that window are disqualified for further use (Bartosz Grzywacz, MD, personal

communication 4/6/2020). In this context, Barter et al. (Barter et al., 2008) found no difference in MPPGL values determined directly from a fresh tissue sample (21.9 ± 0.3 mg/g) compared with the value determined after thawing a matching snap-frozen sample (23.5 ± 1.2 mg/g). The University of Maryland Brain and Tissue Bank for Developmental Disorders was founded in 1991 in response to the need for increased research on developmental disorders impacting children. Now part of the NIH NeuroBioBank network, the UMBTB continues to receive tissue donations from families; after the consent process has been completed, tissues are harvested by a medical examiner or forensic pathologist and rinsed with water before freezing and transfer to the Biobank, essentially autopsy samples (<https://www.medschool.umaryland.edu/btbank/Medical-Examiners-and-Pathologists/Consent-and-Tissue-Recovery-Process/>). A third procedure used by commercial entities, such as Sekisui Xenotech, involves tissues obtained through partnerships with non-profit organ procurement organizations managed by the regional Organ Procurement and Transplantation Networks that are regulated by the United Network for Organ Sharing (UNOS; Richmond, VA) and ultimately deemed unsuitable for transplant. After harvest, tissues are perfused with a preservation buffer and kept on wet ice until unpacked by the recipient organization and flash frozen. Continual improvement in the preservation solutions is a science of its own, with the goal of minimizing ischemia damage and increasing transplant success (Petrenko et al., 2019).

Although tissues available through UMBTB had slightly shorter post-mortem intervals (12.1 ± 3.1 hour) compared with organizations acquiring livers preserved in some manner between explantation and acquisition (Sekisui-XenoTech 15.1 ± 5.9 hour; University of Pittsburgh 15.6 ± 9.2 hour), differences in RNA quality were apparent, with the UMBTB samples having lower RQI values than the other three primary sources of tissues. Similar differences were observed for POR activity, selected as the microsomal marker activity as considerably less sample is required compared with the amount required for carbon monoxide binding spectra, an important consideration given the limited amount of tissue (~ 1 g or less) available for some samples. POR activity correlated with POR protein abundance determined by quantitative proteomic determination and POR activity, ($r^2=0.679$, $P < 0.0001$), but lower activity and protein abundance were observed in the UMBTB samples relative to the other sources, providing confidence in POR activity as a measure of tissue quality and marker of microsomal content and recovery.

To the extent that POR activity in liver homogenates (and subsequently microsomes) can be used as a measure of tissue quality, UMBTB/autopsy livers in the “trimmed” dataset used for assessing source effects had considerably lower POR activity (and microsomal POR protein abundance) than the other sources. However, as calculation of MPPGL essentially is based on the ratio of POR_{Hom} and POR_{Mic} (Eq. 3), MPPGL values for the UMBTB samples tended to be lower




Fig. 2. Effect of tissue source on POR activity and recovery of microsomes in the “trimmed” dataset. The dataset was reduced to a set of samples encompassing an age range, 3 years to 18 years of age, that was common to each major source of tissues. The effect of tissue source was assessed for POR activity per mg tissue homogenate protein (Panel A) and per mg microsomal protein (panel B), per nmol POR protein determined by quantitative proteomics (Panel C), and microsomal POR activity expressed relative to POR protein (Panel D). POR activity in microsomes correlated with microsomal POR protein content (Panel E), although activity was lower in UMBTB samples than non-UMBTB samples for a given amount of POR protein. The effect of tissue source on absolute recovery of microsomal protein




Fig. 3. Effect of tissue source on log-transformed MPPGL values in the trimmed dataset. Samples are color-coded by age category as described in the legend to Fig. 2. logMPPGL values were significantly greater in samples from the University of Minnesota compared with the other sources by Tukey's HSD.

and more variable than the Sekisui-Xenotech and Pittsburgh samples such that it was difficult to detect a difference among the three groups (Fig. 3). Taking the considerations above into account, we conclude that liver tissue samples acquired through UMBTB are different from the LTCDS sites at the Universities of Minnesota and Pittsburgh and Sekisui-Xenotech, and some of the differences in POR activities may be due to tissue quality. However, we note that as UMBTB was originally developed to serve as a resource for research in developmental disorders primarily affecting children, a state of chronic illness preceding death may also contribute to the observed differences in POR activities in UMBTB samples relative to other groups. On the other hand, estimation of MPPGL in UMBTB tissues based on the ratio of POR values implies

that MPPGL values in these samples are within the range of values derived from the other major sources. Furthermore, among the pediatric samples, UMBTB samples are over-represented in the younger age groups (infant and toddler stages, in particular).

Given the effect of tissue source on POR activity and thus, MPPGL values, a value of 30.4 ± 1.7 is representative of an age range of one month to early adulthood resulting from this analysis (geometric mean of 28.0 ± 1.4 mg/g for the non-UMBTB trimmed data set) and represents the best estimate of MPPGL for the pediatric age range. We acknowledge that there may be different approaches to investigate the effect of age on MPPGL (or lack thereof), and therefore, the MPPGL value for each sample included in this analysis is provided in Supplemental Table 2. Nevertheless, the value of 30.4 ± 1.7 mg/g that we report is similar to the value of 32–33 mg/g reported by Barter et al. (Barter et al., 2007; Barter et al., 2008), and somewhat higher than the value of 18.7 ± 2.8 mg/g derived from four pediatric liver samples obtained from infants/young children with biliary atresia as reported by De Bock et al. (De Bock et al., 2014). This latter value is striking in its similarity to the geometric mean value of 18.6 ± 1.6 mg/g for the UMBTB samples (and higher than a value of 11.7 mg/g at age 9 years using the regression equation for UMBTB samples) in our study, possibly reflecting a disease-related effect, although not necessarily directly affecting the liver of patients suffering from chronic disease. Beyond estimates of average values of MPPGL for use in modeling and simulation, an understanding of the inter-individual variability in MPPGL values at a given age or developmental stage is perhaps equally important, generally varying approximately 4- to 6-fold in the postnatal age groups included in the study.

In summary, this report addresses an important knowledge deficit regarding the ontogeny of a critical scaling factor for extrapolating in vivo drug clearance in pediatric age groups from in vitro drug biotransformation data. The analysis also identified tissue source and quality as potential factors influencing interpretation of the data. During preparation of this manuscript, a paper was published by Doerksen et al. in which several important considerations related to MPPGL and

TABLE 2
Results of logMPPGL regression models

All Samples							
	Coefficient	95% lower	95% upper	Standardized coefficient ¹	95% lower	95% upper	P value
Intercept	1.444	1.390	1.497	8.240	7.934	8.545	
Age (decades)	0.050	0.004	0.095	0.283	0.024	0.541	0.032
Age squared ²	−0.010	−0.084	0.064	−0.057	−0.481	0.368	0.792
POR z-score	0.066	0.047	0.095	0.375	0.209	0.542	<0.001
Non-UMBTB (UMBTB Excluded)							
	Coefficient	95% lower	95% upper	Standardized coefficient ¹	95% lower	95% upper	P value
Intercept	1.515	1.446	1.583	8.644	8.251	9.037	
Age (decades)	0.001	−0.049	0.052	0.007	−0.282	0.297	0.959
Age squared ²	−0.094	−0.198	0.010	−0.538	−1.132	0.057	0.075
POR z-score	0.070	0.032	0.109	0.402	0.184	0.620	<0.001
UMBTB Only							
	Coefficient	95% lower	95% upper	Standardized coefficient ¹	95% lower	95% upper	P value
Intercept	1.069	0.859	1.279	6.100	4.900	7.299	
Age (decades)	0.070	0.001	0.140	0.401	0.004	0.799	0.048
Age squared ²	−0.002	−0.106	0.102	−0.010	−0.605	0.585	0.973
POR z-score	−0.305	−0.517	−0.092	−1.740	−2.953	−0.527	0.006

¹ Log(MPPGL) standardized to have a standard deviation of 1

² Age in decades, centered at age 9, squared

is presented in Panel F. Data points in Panels A–D and F are color-coded by NIH age category: early childhood (green), middle childhood (turquoise) and early adolescence (blue). Data points in Panel E are color coded by tissue source as described in the legend to Fig. 1. Construction of box plots is as described in the legend to Fig. 1; the asterisk designates statistically significant difference by Tukey's HSD as described in Methods.

the related factor cytosolic protein per gram liver are critically reviewed (Doerksen et al., 2021). These authors also emphasize the importance of tissue source, and identify methodological considerations, such as buffers and tissue processing protocols, choice of protein assay, and marker for calculating recovery (e.g., CYP content, POR activity) as additional factors of importance. In addition to the source-dependent effect on POR reported in this paper, we have observed similar effects on CYP3A4 activity (and other CYPs; unpublished data) and naltrexol formation (attributed to aldo-keto reductase family 1, member C4) in cytosols prepared from the same liver samples (Stancil et al., in press). Given the limited number of quality pediatric tissues available for research, standardization of efforts to generate high-quality pediatric data from multiple tissue sources will lead to refinement of developmental trajectories beyond those currently available (for example, UMBTB samples reported in Stevens et al., 2003 and Koukouritaki et al., 2004) and ultimately, improved modeling and simulation for pediatric applications.

Authorship Contributions

Participated in research design: Leeder, Dinh, Pearce.

Conducted experiments: Gaedigk, Prasad, Pearce.

Contributed new reagents or analytic tools: Leeder, Prasad, Pearce.

Performed data analysis: Leeder, Staggs.

Wrote or contributed to the writing of the manuscript: Leeder, Dinh, Gaedigk, Staggs, Prasad, Pearce.

References

- Anderson BJ and Holford NHG (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. *Annu Rev Pharmacol Toxicol* **48**:303–332.
- Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR et al. (2007) Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. *Curr Drug Metab* **8**:33–45.
- Barter ZE, Chowdry JE, Harlow JR, Snawder JE, Lipscomb JC, and Rostami-Hodjegan A (2008) Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. *Drug Metab Dispos* **36**:2405–2409.
- Bhatt DK, Basit A, Zhang H, Gaedigk A, Lee SB, Claw KG, Mehrotra A, Chaudhry AS, Pearce RE, Gaedigk R et al. (2018) Hepatic abundance and activity of androgen- and drug-metabolizing enzyme UGT2B17 are associated with genotype, age, and sex. *Drug Metab Dispos* **46**:888–896.
- Bhatt DK and Prasad B (2018) Critical issues and optimized practices in quantification of protein abundance level to determine interindividual variability in DMET proteins by LC-MS/MS proteomics. *Clin Pharmacol Ther* **103**:619–630.
- Calvier EAM, Krekels EHI, Johnson TN, Rostami-Hodjegan A, Tibboel D, and Knibbe CAJ (2019) Scaling drug clearance from adults to young children for drugs undergoing hepatic metabolism: A simulation study to search for the simplest scaling method. *AAPS J* **21**:38.
- Calvier EAM, Krekels EHI, Väitalo PAJ, Rostami-Hodjegan A, Tibboel D, Danhof M, and Knibbe CAJ (2017) Allometric scaling of clearance in pediatric patients: when does the magic of 0.75 fade? *Clin Pharmacokinet* **56**:273–285.
- De Bock L, Boussery K, De Bruyne R, Van Winckel M, Stephen X, Sokal E, and Van Bocxlaer J (2014) Microsomal protein per gram of liver (MPPGL) in paediatric biliary atresia patients. *Biopharm Drug Dispos* **35**:308–312.
- Doerksen MJ, Jones RS, Coughtrie MWH, and Collier AC (2021) Parameterization of microsomal and cytosolic scaling factors: Methodological and biological considerations for scalar derivation and validation. *Eur J Drug Metab Pharmacokin* **2**:173–183.
- Edginton AN and Willmann S (2006) Physiology-based versus allometric scaling of clearance in children: an eliminating process-based comparison. *Paediatr Perinat Drug Ther* **7**:146–153.
- Germovsek E, Barker CIS, Sharland M, and Standing JF (2019) Pharmacokinetic-pharmacodynamic modeling in pediatric drug development, and the importance of standardized scaling of clearance. *Clin Pharmacokinet* **58**:39–52.
- Hakooz N, Ito K, Rawden H, Gill H, Lemmers L, Boobis AR, Edwards RJ, Carlile DJ, Lake BG, and Houston JB (2006) Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. *Pharm Res* **23**:533–539.
- Johnson TN, Tucker GT, Tanner MS, and Rostami-Hodjegan A (2005) Changes in liver volume from birth to adulthood: a meta-analysis. *Liver Transpl* **11**:1481–1493.
- Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, and Hines RN (2004) Developmental expression of human hepatic CYP2C9 and CYP2C19. *J Pharmacol Exp Ther* **308**:965–974.
- Krekels EHI, van Hasselt JGC, van den Anker JN, Allegaert K, Tibboel D, and Knibbe CAJ (2017) Evidence-based drug treatment for special patient populations through model-based approaches. *Eur J Pharm Sci* **109S**:S22–S26.
- Lu AY and Levin W (1972) Partial purification of cytochromes P-450 and P-448 from rat liver microsomes. *Biochem Biophys Res Commun* **46**:1334–1339.
- Maharaj AR and Edginton AN (2014) Physiologically based pharmacokinetic modeling and simulation in pediatric drug development. *CPT Pharmacometrics Syst Pharmacol* **3**:e150.
- Mahmood I, Staschen C-M, and Goteti K (2014) Prediction of drug clearance in children: an evaluation of the predictive performance of several models. *AAPS J* **16**:1334–1343.
- Neely M, Bayard D, Desai A, Kovanda L, and Edginton A (2018) Pharmacometric modeling and simulation is essential to pediatric clinical pharmacology. *J Clin Pharmacol* **58** (Suppl 10):S73–S85.
- Petrenko A, Camevale M, Somov A, Osorio J, Rodriguez J, Guibert E, Fuller B, and Froghi F (2019) Organ preservation into the 2020s: The era of dynamic intervention. *Transfus Med Hemother* **46**:151–172.
- Salerno SN, Edginton A, Gerhart JG, Laughon MM, Ambalavanan N, Sokol GM, Homik CD, Stewart D, Mills M, Martz K et al.; Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee (2021) Physiologically-based pharmacokinetic modeling characterizes the CYP3A-mediated drug-drug interaction between fluconazole and sildenafil in infants. *Clin Pharmacol Ther* **109**:253–262.
- Stancil SL, Nolte W, Pearce RE, Staggs VS, and Leeder JS (2021) The impact of age and genetics on naltrexone biotransformation. *Drug Metab Dispos*, in press DOI: 10.1124/dmd.121.000646.
- Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, Tandler PJ, and Zaya MJ (2003) Developmental expression of the major human hepatic CYP3A enzymes. *J Pharmacol Exp Ther* **307**:573–582.
- Williams K, Thomson D, Seto I, Contopoulos-Ioannidis DG, Ioannidis JPA, Curtis S, Constantin E, Batmanabane G, Hartling L, and Klassen T; StaR Child Health Group (2012) Standard 6: age groups for pediatric trials. *Pediatrics* **129** (Suppl 3):S153–S160.
- Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW, and Tucker GT (2003) Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. *Br J Clin Pharmacol* **56**:433–440.
- Zhang H, Gao N, Tian X, Liu T, Fang Y, Zhou J, Wen Q, Xu B, Qi B, Gao J et al. (2015) Content and activity of human liver microsomal protein and prediction of individual hepatic clearance in vivo. *Sci Rep* **5**:17671.

Address correspondence to: Dr. J. Steven Leeder, Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, 2401 Gillham Rd, Kansas City, MO 64108. E-mail: sleeder@cmh.edu

Supplemental Data

Ontogeny of Scaling Factors for Pediatric PBPK Modeling and Simulation: Microsomal Protein
Per Gram of Liver

J. Steven Leeder, Jean C. Dinh, Andrea Gaedigk, Vincent S. Staggs, Bhagwat
Prasad, Robin E. Pearce

Drug Metabolism and Disposition

Manuscript # DMD-AR-2021-000623

Supplemental Table 1: Distribution of liver samples by age and source

Supplemental Table 2: Individual sample demographic, POR and MPPGL data

Supplemental Table 3: Optimized LC and MS/MS parameters used for quantification of selected surrogate peptide (light) and corresponding internal standard (heavy) of CYP reductase

Supplemental Figure 1: Distribution of MPPGL and logMPPGL values. Symbols are color-coded according to NICHD-assigned age group as presented in Supplemental Table 1: red, prenatal; orange, infant; yellow, toddler; green, early childhood; turquoise, middle childhood; blue, early adolescent; gray, younger adult; black, older adult (>50 years)

Supplemental Table 1: Distribution of liver samples by age and source

	Age Group/Developmental Stage						
	Infant	Toddler	Early Childhood	Middle Childhood	Early Adolescent	Younger Adult	Older Adult
Source	(Group 1)	(Group 2)	(Group 3)	(Group 4)	(Group 5)	(Group 6)	(Group 7)
Minnesota (n=34)	0	2	7	13	12	0	0
Pittsburgh (n=37)	0	0	1	8	5	8	15
UMB (n=60)	14	3	7	7	21	8	0
Xenotech (n=23)	4	4	6	3	6	0	0
Vitron (n=4)	0	0	0	1	3	0	0
Other (n=2)	2	0	0	0	0	0	0
TOTAL (n=160)	20	9	21	32	47	16	15

Supplemental Table 2: Demographic, POR and MPPGL Data

Assigned ID	Postnatal Age (yr) ¹	Age_NICHD ²	Source ³	Sex	Ethnicity	Cause of Death	Smoking and Drinking Status ⁴ and Medication use ⁵	micPOR Protein ⁶	micPOR Activity ⁷	MPPGL (mg/g)
64	15	5	UMBTB	Male	African American	Motor vehicle accident	None reported		44.4	12.0
86	0.15	1	UMBTB	Male	Caucasian	Congenital Heart Defect	None reported	5.6	29.5	9.3
95	15	5	UMBTB	Male	Hispanic	Depression/Accident, multiple injuries	Toxicology report negative for drugs and alcohol	12.2	42.2	11.7
99	6	4	Xenotech	Male	Caucasian	Unknown	Not prescribed any medications	23.8	172.3	28.6
105	14.84	5	UMBTB	Male	Caucasian	Accident, multiple injuries	None reported	4.2	4.4	29.4
142	16.2	5	UMBTB	Male	Caucasian	Accident, massive head injuries	None reported	17.3	102.4	9.9
195	0.34	1	UMBTB	Male	African American	Complications of prematurity	None reported	12.9	96.4	10.4
260	2	2	Xenotech	Male	Caucasian	Anoxia	No alcohol, drug or tobacco use; furosemide, insulin	19.1	146.0	19.3
271	0.055	1	UMBTB	Male	African American	Asphyxia	None reported	4.6	2.7	34.0
283	0.54	1	UMBTB	Male	African American	Asthma	Proventil 2.5 mg tid	17.4	55.3	9.2
289	24.99	6	UMBTB	Male	African American	Heroin overdose	None reported		2.9	34.4
322	1	1	Xenotech	Male	Hispanic	Choking (solid foreign object)	No alcohol, drug or tobacco use	13.9	76.3	14.6
326	14	5	Xenotech	Female	Caucasian	Anoxia	No alcohol, drug or tobacco use; enalapril	15.1	94.4	20.9
346	3	3	Xenotech	Male	Caucasian	Intracranial hemorrhage	None reported	49.6	279.7	27.7
356	8.07	4	UMBTB	Male	African American	Accident, multiple injuries	None reported	3.3	3.1	47.9
372	3.02	3	UMBTB	Male	Caucasian	Complications of cerebral palsy	None reported	15.9	47.3	21.2
416	18	5	Xenotech	Male	Caucasian	Anoxia	Unspecified medications for spina bifida	11.6	68.3	22.1
435	0.75	1	UMBTB	Male	Caucasian	Meningitis	None reported	8.7	29.7	8.1
451	4.56	3	UMBTB	Male	Caucasian	Accidental drowning	None reported	20.1	109.8	11.1
497	12.42	5	UMBTB	Male	Caucasian	Accidental drowning	None reported	10.7	47.7	15.4
551	2	2	Xenotech	Male	Caucasian	Head trauma secondary to motor vehicle accident	None reported	18.7	125.1	26.6
569	0.36	1	UMBTB	Male	Caucasian	Accidental, exposure	None reported; "exposure" not defined	15.2	79.4	12.6
591	11	4	Xenotech	Female	Caucasian	Motor vehicle accident	None reported		333.8	19.5
596	17	5	Xenotech	Female	Caucasian	Motor vehicle accident	Smoker (1.5 packs per week x 4 yr); no alcohol use; no medications	18.8	151.0	32.9
613	14	5	UMBTB	Male	Caucasian	Alexander Disease/complications of disorder	None reported	20.6	37.1	20.0
617	1.95	2	UMBTB	Female	Caucasian	Pneumonia	None reported; developmentally delayed and history of seizures with last <1 month before death	6.1	8.2	18.5
620	14.32	5	UMBTB	Male	African American	Cardiomyopathy	None reported	11.0	38.3	14.1
634	46.67	6	UMBTB	Male	Caucasian	Arteriosclerotic cardiovascular disease	Heavy smoker and diabetic		23.5	7.9
671	0.25	1	Xenotech	Male	Hispanic	Sudden infant death syndrome	None reported	21.8	134.3	23.6
675	5	3	Xenotech	Male	Caucasian	Hydrocephalus	Metoclopramide, omeprazole, gabapentin, multi-vitamin	11.5	91.2	16.4
677	1.97	2	UMBTB	Male	African American	Cardiac arrhythmia	None reported	1.3	1.0	44.2
689	5	3	Xenotech	Female	Caucasian	Head trauma	None reported	19.7	162.4	25.2
695	21.49	6	UMBTB	Male	Caucasian	Accident, multiple injuries	None reported		9.1	18.8
737	7.34	4	UMBTB	Female	African American	Complications of cerebral palsy	None reported	8.7	12.8	18.3
738	8.92	4	UMBTB	Female	Caucasian	Cardiac arrhythmia	None reported	10.7	39.9	12.9
754	11.54	4	UMBTB	Female	Pacific islander	Asthma	Nebulized albuterol, unspecified inhalers, fluoxetine	10.7	34.2	8.8
759	0.1	1	UMBTB	Male	Caucasian	Idopathic pulmonary hemorrhage	None reported	12.2	58.5	15.3
771	2.75	3	UMBTB	Male	African American	Subaortic valvular stenosis	None reported	9.8	47.3	14.8
774	0.75	1	UMBTB	Male	Caucasian	Sudden infant death syndrome	None reported; history of larynx and respiratory problems	6.8	12.1	22.3
776	4	3	Xenotech	Female	African American	Obstructed VP shunt	Baclofen, lorazepam, phenobarbital, topiramate, ibuprofen, acetaminophen, enoxapirin, polyvitamin	19.6	132.9	28.9
777	22.92	6	UMBTB	Male	African American	Arteriosclerotic cardiovascular disease	None reported		51.7	25.2
780	0	1	UMBTB	Male	African American	Drowning upon delivery; mother claimed stillborn but autopsy proved baby took breath	None reported	7.4	33.0	8.5
781	15	5	Xenotech	Female	Caucasian	Cerebrovascular accident/seizures	No alcohol, drug, tobacco use; Clonazepam, valproic acid, zonisamide	22.0	147.3	13.1
792	4	3	Xenotech	Male	Native American	Head trauma	None reported	17.7	176.7	13.0
811	16	5	Xenotech	Male	Caucasian	Head trauma secondary to motor vehicle accident	Topical accutane	6.4	74.5	14.5
825	0.92	1	Xenotech	Male	Caucasian	Anoxia	Hydrocortisone	16.6	175.1	19.4
845	0.08	1	Xenotech	Male	Caucasian	Anoxia - blunt injury	Amoxicillin	13.3	221.1	19.5
852	2	2	Xenotech	Male	Hispanic	Head trauma secondary to blunt injury	None reported	20.6	182.5	17.3
866	3	3	Xenotech	Female	Caucasian	Closed head injury	None reported	21.5	120.0	34.8
872	2	2	Xenotech	Male	Caucasian	Anoxia secondary to drowning	None reported	30.8	187.8	24.5
885	17	5	Xenotech	Male	African American	Head trauma secondary to motor vehicle accident	No alcohol or tobacco use; marijuana on one occasion	17.8	99.9	26.2
1055	0.26	1	UMBTB	Male	Caucasian	Bronchopneumonia	Infant tylenol	4.6	1.4	25.9
1078	17.08	5	UMBTB	Female	Caucasian	Motor vehicle accident, multiple injuries	None reported		5.7	30.3
1157	0.05	1	UMBTB	Female	Caucasian	Pneumonia associated with meconium aspiration	None reported	12.1	10.3	14.7
1181	8.17	4	UMBTB	Male	Caucasian	Lennox-Gasaut Syndrome/Epilepsy seizure disorder	Felbamate 600/5ml, topiramate 25 mg	10.4	4.9	21.0
1256	13.86	5	UMBTB	Male	Caucasian	Hanging	Methylphenidate	5.0	8.1	20.6
1259	24.99	6	UMBTB	Male	Caucasian	Compressional asphyxia related to motor vehicle accident	None reported		2.8	81.2
1284	3.34	3	UMBTB	Female	African American	Drowning	None reported	12.9	64.1	16.0
1296	0.27	1	UMBTB	Male	African American	Tetralogy of Fallot	Furosemide, potassium	3.3	4.5	19.5
1297	15.22	5	UMBTB	Male	African American	Multiple injuries due to motor vehicle accident	None reported	8.7	23.2	36.1
1443	0.91	1	UMBTB	Female	African American	Bronchiolitis associated with laryngitis	None reported	10.1	24.9	24.2
1475	20.31	6	UMBTB	Male	Caucasian	Motor vehicle accident	None reported		30.5	21.8
1542	22.98	6	UMBTB	Male	African American	Motor vehicle accident	None reported		37.0	14.4

Supplemental Table 2: Demographic, POR and MPPGL Data

Assigned ID	Postnatal Age (yr) ¹	Age_NICHD ²	Source ³	Sex	Ethnicity	Cause of Death	Smoking and Drinking Status ⁴ and Medication use ⁵	micPOR Protein ⁶	micPOR Activity ⁷	MPPGL (mg/g)
1547	1.71	2	UMBTB	Male	African American	Asthma	Albuterol nebulizer, diphenhydramine	20.8	100.4	9.2
1624	3.16	3	UMBTB	Female	Caucasian	Complications of Batten's Disease	None reported	36.8	125.5	14.2
1670	13.27	5	UMBTB	Male	Caucasian	Asphyxia by hanging	Negative for alcohol	6.6	9.1	19.4
1737	34.98	6	UMBTB	Female	African American	Exsanguination	None reported		9.9	69.8
1791	2.78	3	UMBTB	Female	African American	Drowning	None reported	15.1	58.9	15.5
1843	15.94	5	UMBTB	Female	Caucasian	Multiple injuries due to car crash	None reported		57.2	16.9
1860	8.01	4	UMBTB	Male	Caucasian	Cardiac arrhythmia	None reported	9.2	27.1	19.3
1904	0.27	1	UMBTB	Male	African American	Dehydration; infant reportedly ill for couple of days	None reported	8.4	28.3	9.5
1908	13.99	5	UMBTB	Male	Caucasian	Accidental hanging	None reported	8.4	32.0	12.2
4591	16.64	5	UMBTB	Female	Caucasian	Multiple injuries	None reported	8.0	11.3	25.7
4638	15.12	5	UMBTB	Female	Caucasian	Chest injuries due to car crash	None reported	8.4	26.5	21.2
4722	14.54	5	UMBTB	Male	Caucasian	Multiple injuries due to all terrain vehicle accident	Nonsmoker	3.5	2.1	60.2
4787	12.87	5	UMBTB	Male	African American	Asthma	Montelukast, albuterol, prednisone, loratidine	14.5	45.3	12.2
4906	16.75	5	UMBTB	Female	Caucasian	Head Injuries	None reported	11.1	31.2	13.2
4907	4.75	3	UMBTB	Female	African American	Asthma	Not available	13.5	52.1	13.3
4925	13.16	5	UMBTB	Male	African American	Natural/possible asthma/allergy death	Albuterol	9.4	6.1	20.8
5077	16.71	5	UMBTB	Female	Caucasian	Multiple injuries due to motorcycle accident	None reported	5.7	3.6	32.4
5173	10.76	4	UMBTB	Female	Caucasian	Asthma	None reported	16.4	52.1	15.5
5242	15.33	5	UMBTB	Male	Caucasian	Cardiac arrhythmia due to conduction system	No history of drug or alcohol abuse	8.6	24.2	33.9
8703	10	4	Minnesota	Female	Unknown	Unknown	Not available	19.1	95.2	20.9
8804	14	5	Minnesota	Male	Unknown	Unknown	Not available	12.4	54.3	32.7
8901	6	4	Minnesota	Female	Unknown	Unknown	Not available	20.6	103.0	23.5
8902	7	4	Minnesota	Male	Unknown	Unknown	Not available	11.7	77.4	30.8
8906	12	5	Minnesota	Male	Unknown	Unknown	Not available	28.2	75.9	45.8
8909	9	4	Minnesota	Female	Unknown	Unknown	Not available	14.0	68.0	42.3
8910	14	5	Minnesota	Male	Unknown	Unknown	Not available	16.1	82.8	41.9
8912	12	5	Minnesota	Female	Unknown	Unknown	Not available	14.6	81.9	34.3
8917	6	4	Minnesota	Female	Unknown	Unknown	Not available	13.4	89.9	46.3
8920	11	4	Minnesota	Male	Unknown	Unknown	Not available	15.4	95.2	49.1
8924	9	4	Minnesota	Female	Unknown	Unknown	Not available	15.6	66.5	44.2
8925	8	4	Minnesota	Male	Unknown	Unknown	Not available	21.5	123.7	26.9
8926	1.83	2	Minnesota	Female	Unknown	Unknown	Not available	12.3	97.7	25.0
8935	17	5	Minnesota	Male	Unknown	Unknown	Not available	11.3	85.1	34.5
9003	7	4	Minnesota	Female	Unknown	Unknown	Not available	21.7	124.5	45.9
9005	17	5	Minnesota	Male	Unknown	Unknown	Not available	17.4	118.0	27.0
9006	10	4	Minnesota	Male	Unknown	Unknown	Not available	28.8	147.8	40.1
9011	3.5	3	Minnesota	Female	Unknown	Unknown	Not available	22.2	120.6	34.0
9013	11	4	Minnesota	Male	Unknown	Unknown	Not available	12.2	78.9	49.0
9022	5	3	Minnesota	Unknown	Unknown	Unknown	Not available	19.6	109.0	42.9
9023	2.58	3	Minnesota	Female	Unknown	Unknown	Not available	40.0	202.4	39.1
9027	12	5	Minnesota	Male	Unknown	Unknown	Not available	14.2	92.9	32.6
9028	8	4	Minnesota	Female	Unknown	Unknown	Not available	13.2	103.8	12.1
9031	17	5	Minnesota	Female	Unknown	Unknown	Not available	20.4	135.7	29.8
9032	14	5	Minnesota	Male	Unknown	Unknown	Not available	18.9	135.1	26.5
9036	5	3	Minnesota	Female	Unknown	Unknown	Not available	19.4	158.3	30.8
9101	2	2	Minnesota	Male	Unknown	Unknown	Not available	26.5	140.1	36.5
9105	17	5	Minnesota	Male	Unknown	Unknown	Not available	17.8	97.2	41.8
9127	15	5	Minnesota	Male	Unknown	Unknown	Not available	22.4	108.2	49.9
9507	14	5	Minnesota	Male	Unknown	Unknown	Not available	18.2	95.3	24.1
9608	4	3	Minnesota	Male	Unknown	Unknown	Not available	24.2	120.0	34.8
9609	4	3	Minnesota	Male	Unknown	Unknown	Not available	19.8	93.1	39.2
9611	9	4	Minnesota	Male	Unknown	Unknown	Not available	16.4	89.0	31.2
9612	3	3	Minnesota	Male	Unknown	Unknown	Not available	20.9	91.3	41.7
70863	73	7	Pittsburgh	Male	Caucasian	Head trauma/fall	No history of smoking or drinking reported; no medications reported		32.0	66.7
70874	6	4	Pittsburgh	Male	African American	Motor vehicle accident/head trauma	No history of smoking or drinking reported; methylphenidate	13.8	70.8	21.9
70879	41	6	Pittsburgh	Female	African American	Anoxia	No history of smoking or drinking reported; furosemide, "premail" (possibly "Prinivil" - lisinopril?)		142.1	38.1
70896	7	4	Pittsburgh	Male	Caucasian	Seizure/respiratory arrest	No history of smoking or drinking reported; "bectofen" (baclofen?), tizanidine, erythromycin, "cloivazepam" (clonazepam?), mometasone nasal, loratidine, omeprazole, Miralax, phenobarbital, melatonin, albuterol, "cromocyn (cromolyn?)	19.0	147.3	21.7
70898	7	4	Pittsburgh	Male	Caucasian	Head trauma, motor vehicle accident	No history of smoking or drinking reported; no medications reported	35.2	214.0	16.9
70909	58	7	Pittsburgh	Female	African American	Cerebrovascular accident	No history of smoking or drinking reported; aspirin, coumadin, losartan, enoxaparin, oxybutynin, simvastatin, Colace		105.6	38.4

Supplemental Table 2: Demographic, POR and MPPGL Data

Assigned ID	Postnatal Age (yr) ¹	Age_NICHD ²	Source ³	Sex	Ethnicity	Cause of Death	Smoking and Drinking Status ⁴ and Medication use ⁵	micPOR Protein ⁶	micPOR Activity ⁷	MPPGL (mg/g)
70917	29	6	Pittsburgh	Male	African American	Intracranial bleed	No history of smoking or drinking reported; no medications reported		137.9	23.3
70921	6	4	Pittsburgh	Female	Caucasian	Head trauma from motor vehicle accident	No history of smoking or drinking reported; enalapril	24.1	130.1	22.9
70931	51	7	Pittsburgh	Female	African American	Subarachnoid hemorrhage	Non-smoker; 7 drinks/wk; marijuana, coumadin, nephrovite, nifedipine, atenolol, phenytoin		189.6	39.5
70939	63	7	Pittsburgh	Female	African American	Intracerebral hemorrhage	No history of smoking or drinking reported; carvedilol, coumadin, "patessin" (pantesin/pantethine/vitamin B57), furosemide, "micardia" (Micardis/telmisartan?), metformin		156.8	24.6
70953	7	4	Pittsburgh	Female	Caucasian	Anoxic brain injury	No history of smoking or drinking reported; gabapentin, carbamazepine, phenobarbital, L-thyroxine	24.1	150.6	40.4
70958	8	4	Pittsburgh	Male	Unknown	Head trauma, motor vehicle accident	No history of smoking or drinking reported; no medications reported	15.6	99.1	17.4
70985	57	7	Pittsburgh	Female	African American	Intracranial bleed	Smoker (1.5 ppd x 45 y); non-drinker; omeprazole, phenytoin		207.4	37.7
70994	16	5	Pittsburgh	Male	Caucasian	Head trauma from motor vehicle accident	No history of smoking or drinking reported; no medications reported	16.3	144.3	20.9
70997	44	6	Pittsburgh	Male	African American	Intracranial bleed	Smoking status uncertain; 100 drinks/wk; crack cocaine, marijuana; coumadin (non-compliant)		161.3	62.5
71000	6	4	Pittsburgh	Male	Caucasian	Head trauma, internal injuries from motor vehicle accident	No history of smoking or drinking reported; no medications reported	16.9	107.3	29.0
71002	5	3	Pittsburgh	Male	Caucasian	Head trauma, motor vehicle accident	No history of smoking or drinking reported; no medications reported	11.6	79.7	50.2
71019	40	6	Pittsburgh	Female	Hispanic	Intracerebral hemorrhage	No history of smoking or drinking reported; unknown thyroid medication		171.1	30.3
71034	41	6	Pittsburgh	Female	African American	Cardiac arrest	No history of smoking or drinking reported; no medications reported		107.7	22.1
71046	66	7	Pittsburgh	Male	Caucasian	Subarachnoid hemorrhage	Smoker (1 ppd x 45y); non-drinker; hypertension meds (unknown), steroids for muscle disease(unknown)		100.3	19.8
71062	39	6	Pittsburgh	Male	African American	Cerebrovascular accident	Smoker (1 ppd x 22 yr); 28 drinks/wk; cocaine "as often as possible"		104.4	19.9
71121	65	7	Pittsburgh	Female	Caucasian	Cerebrovascular accident/intracranial hemorrhage	Smoker (2 ppd x 50 yr); 1 drink/wk; "sripton"		74.3	18.8
71165	16	5	Pittsburgh	Female	Caucasian	Head trauma, motor vehicle accident	No history of smoking or drinking reported; no medications reported	10.8	78.2	22.0
71201	69	7	Pittsburgh	Male	Caucasian	Cerebrovascular accident/anoxia	Smoker (3 ppd x 40 yr); 105 drinks/wk; aspirin, clopidogrel, carvedilol, simvastatin, pantoprazole, torsemide, "tetia" (Zetia/ezetimibe?)		134.2	27.3
71209	30	6	Pittsburgh	Female	Caucasian	Cerebrovascular accident/stroke	No history of smoking or drinking reported; Depo-Provera		147.0	28.0
71211	79	7	Pittsburgh	Male	African American	Cerebrovascular accident/anoxia	No history of smoking or drinking reported; insulin		132.2	19.0
71223	58	7	Pittsburgh	Female	Caucasian	Cerebrovascular accident/anoxia	No history of smoking or drinking reported; no medications reported		188.0	19.7
71226	53	7	Pittsburgh	Male	Caucasian	Head Trauma/SIGSW	Smoker (0.5 ppd x 35 years); 42 drinks/wk; escitalopram and un-specified hypertension medications		99.5	32.1
71246	70	7	Pittsburgh	Male	Caucasian	Head trauma	Non-smoker; 2 drinks/wk; clopidogrel, coumadin, insulin, lovastatin, atenolol, metformin, glyburide		87.6	42.6
71248	42	6	Pittsburgh	Female	Caucasian	Subarachnoid hemorrhage	Smoker (1 ppd x 26 y); non-drinker; amytriptyline, coumadin, oxycontin, hydrocodone+acetaminophen (Lortab), furosemide		116.4	26.6
71249	59	7	Pittsburgh	Male	Hispanic	Cerebrovascular accident	Smoker (1 ppd x 9 yr); 3 drinks/wk; insulin, aspirin, folic acid, "lant US", escitalopram, calcitriol, "cadvet" (Caduet/amlodipine+atorvastatin?)		124.0	33.3
71278	59	7	Pittsburgh	Male	Caucasian	Cerebrovascular accident	No history of smoking or drinking reported; OTC Tylenol allergy product		113.9	45.6
71281	16	5	Pittsburgh	Male	Caucasian	Head trauma, motor vehicle accident	No history of smoking or drinking reported; no medications reported	17.0	105.3	23.6
71299	57	7	Pittsburgh	Male	African American	Intracerebral hemorrhage	No history of smoking or drinking reported; no medications reported		135.8	24.0
71307	12	5	Pittsburgh	Female	Caucasian	Anoxia	No history of smoking or drinking reported; no medications reported	30.8	187.5	21.8
71414	8	4	Pittsburgh	Male	Caucasian	Anoxia	No history of smoking or drinking reported; no medications reported	16.7	104.3	20.7
71649	15	5	Pittsburgh	Female	Caucasian	Motor vehicle accident; anoxia	No information available	23.7	142.9	25.0
76351	0.9	1	AHTU	Male	Hispanic	Complications of urea cycle disorder	No information available		164.0	49.1
85551	8	4	Vitron	Male	African American	Cardiac arrest	Methylphenidate, digoxin, amoxicillin	20.5	77.8	57.4
85651	12	5	Vitron	Female	African American	Subarachnoid hemorrhage	No medications reported	12.5	77.0	45.5
85891	17	5	Vitron	Female	Caucasian	Massive cerebral edema	Imipramine and unspecified inhaler	15.6	128.1	22.7
86461	18	5	Vitron	Female	Caucasian	Head trauma	No medications reported	12.1	101.8	18.5
93827	0.25	1	Miami	Male	Caucasian	Unknown	No information available		89.1	22.1
99377	11	4	Xenotech	Male	Caucasian	Anoxia secondary to smoke inhalation	Toxicology screen negative	13.9	100.7	24.9

Supplemental Table 2: Demographic, POR and MPPGL Data

Assigned ID	Postnatal Age (yr) ¹	Age_NICHD ²	Source ³	Sex	Ethnicity	Cause of Death	Smoking and Drinking Status ⁴ and Medication use ⁵	micPOR Protein ⁶	micPOR Activity ⁷	MPPGL (mg/g)
¹ Arbitrary values of -0.4 assigned to prenatal samples										
² Age group according to NICHD categories as described in the text										
³ Source of liver samples as described in Methods										
⁴ "No history of smoking or drinking reported" indicates that smoking was reported as "0" and drinking was reported as "0"										
⁵ Chronic medications as reported in the information accompanying the samples (uncertain identifications are identified by "quotation marks" and possible IDs are provided in parentheses); short term medications administered in the emergency room are not included										
⁶ POR abundance in microsomes (nmol/mg microsomal protein)										
⁷ Microsomal POR activity (nmol/min/mg microsomal protein)										


Supplemental Table 3: Optimized LC and MS/MS parameters used for quantification of selected surrogate peptide (light) and corresponding internal standard (heavy) of CYP reductase

LC gradient program						
Time (min)	Flow Rate	A (Water with 0.1% formic acid, %)		B (Acetonitrile with 0.1% formic acid, %)		
0	0.3	97		3		
4	0.3	97		3		
8	0.3	87		13		
18	0.3	70		30		
20.5	0.3	65		35		
21.1	0.3	40		60		
23.1	0.3	20		80		
23.2	0.3	97		3		
27	0.3	97		3		
MS Parameters						
Protein	Peptide sequence	Light/Heavy	Precursor (<i>m/z</i>)	Product (<i>m/z</i>)	CE (eV)	DP (V)
CYP-reductase (POR)	FAVFGLGNK	Light	476.9	635.3	75	19
			476.9	734.3	75	19
			476.9	488.3	75	19
		Heavy	480.8	643.4	75	19
			480.8	742.4	75	19

* The heavy peptide contains the labeled [¹³C₆¹⁵N₂]-lysine residue.

Supplemental Figure 1:

Distribution of MPPGL (page 1 of 2) and logMPPGL (page 2 of 2) values. Symbols are color-coded according to NICHD-assigned age group as presented in Supplemental Table 1: red, prenatal; orange, infant; yellow, toddler; green, early childhood; turquoise, middle childhood; blue, early adolescent; gray, younger adult; black, older adult (>50 years)

Distributions**MPPGL (Barter Method)****Compare Distributions**

Show	Distribution	AICc ^	BIC	-2*LogLikelihood
<input checked="" type="checkbox"/>	Normal	1285.3216	1291.3955	1281.2451

Summary Statistics

Mean	26.978108
Std Dev	13.30417
Std Err Mean	1.051787
Upper 95% Mean	29.055384
Lower 95% Mean	24.900833
N	160
Interquartile Range	15.918242

Fitted Normal Distribution


Parameter	Estimate	Std Error	Lower 95%	Upper 95%
Location μ	26.978108	1.051787	24.916644	29.039573
Dispersion σ	13.30417	0.2048633	12.908644	13.464843

Measures

-2*LogLikelihood	1281.2451
AICc	1285.3216
BIC	1291.3955

Goodness-of-Fit Test

	W	Prob<W
Shapiro-Wilk	0.921993	<.0001*

Distributions**logMPPGL (Barter)****Compare Distributions**

Show	Distribution	AICc ^	BIC	-2*LogLikelihood
<input checked="" type="checkbox"/>	Normal	-39.98093	-33.90702	-44.05737

Summary Statistics

Mean	1.3808802
Std Dev	0.2115079
Std Err Mean	0.0167212
Upper 95% Mean	1.4139044
Lower 95% Mean	1.3478559
N	160
Interquartile Range	0.2715149

Fitted Normal Distribution

Parameter	Estimate	Std Error	Lower 95%	Upper 95%
Location μ	1.3808802	0.0167212	1.3481073	1.413653
Dispersion σ	0.2115079	0.0258306	0.1664842	0.2140623

Measures

-2*LogLikelihood	-44.05737
AICc	-39.98093
BIC	-33.90702

Goodness-of-Fit Test

	W	Prob<W
Shapiro-Wilk	0.9918852	0.5018